These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 9843176)

  • 1. Measurement of active coagulation factors in Autoplex-T with colorimetric active site-specific assay technology.
    Lundblad RL; Bergstrom J; De Vreker R; Bray G; Gomperts E; Baker D; Kingdon HS; Mann KG; Hartshorn J; Jenny RJ
    Thromb Haemost; 1998 Nov; 80(5):811-5. PubMed ID: 9843176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between two concentrates with factor VIII inhibitor bypassing activity.
    Vinazzer H
    Thromb Res; 1982 Apr; 26(1):21-9. PubMed ID: 6980497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
    Zhang E; St Charles R; Tulinsky A
    J Mol Biol; 1999 Feb; 285(5):2089-104. PubMed ID: 9925787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig.
    Himber J; Refino CJ; Burcklen L; Roux S; Kirchhofer D
    Thromb Haemost; 2001 Mar; 85(3):475-81. PubMed ID: 11307818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inhibitor coagulant complex (Autoplex) in hemophilia inhibitor patients undergoing synovectomy.
    Hutchinson RJ; Penner JA; Hensinger RN
    Pediatrics; 1983 Apr; 71(4):631-3. PubMed ID: 6601258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ancylostoma ceylanicum anticoagulant peptide-1: role of the predicted reactive site amino acid in mediating inhibition of coagulation factors Xa and VIIa.
    Mieszczanek J; Harrison LM; Cappello M
    Mol Biochem Parasitol; 2004 Sep; 137(1):151-9. PubMed ID: 15279961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the mechanism of action and future of activated prothrombin complex concentrates.
    Turecek PL; Váradi K; Schwarz HP
    Curr Hematol Rep; 2004 Sep; 3(5):331-7. PubMed ID: 15341699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Na+ binding channel of human coagulation proteases: novel insights on the structure and allosteric modulation revealed by molecular surface analysis.
    Silva FP; Antunes OA; de Alencastro RB; De Simone SG
    Biophys Chem; 2006 Feb; 119(3):282-94. PubMed ID: 16288954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two coagulation factor X activators from Vipera a. ammodytes venom with potential to treat patients with dysfunctional factors IXa or VIIa.
    Leonardi A; Fox JW; Trampus-Bakija A; Krizaj I
    Toxicon; 2008 Oct; 52(5):628-37. PubMed ID: 18760294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII.
    Lusher JM; Blatt PM; Penner JA; Aledort LM; Levine PH; White GC; Warrier AI; Whitehurst DA
    Blood; 1983 Nov; 62(5):1135-8. PubMed ID: 6414555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of sodium ion binding on factor IXa activity.
    Gopalakrishna K; Rezaie AR
    Thromb Haemost; 2006 Jun; 95(6):936-41. PubMed ID: 16732371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate-dependent modulation of the mechanism of factor XIa inhibition.
    Pedicord DL; Seiffert D; Blat Y
    Biochemistry; 2004 Sep; 43(37):11883-8. PubMed ID: 15362874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of phage display for the generation of human antibodies that neutralize factor IXa function.
    Suggett S; Kirchhofer D; Hass P; Lipari T; Moran P; Nagel M; Judice K; Schroeder K; Tom J; Lowman H; Adams C; Eaton D; Devaux B
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):27-42. PubMed ID: 10691097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional phenotyping of human plasma using a 361-fluorogenic substrate biosensing microarray.
    Gosalia DN; Denney WS; Salisbury CM; Ellman JA; Diamond SL
    Biotechnol Bioeng; 2006 Aug; 94(6):1099-110. PubMed ID: 16575920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The second epidermal growth factor-like domain of human factor IXa mediates factor IXa binding to platelets and assembly of the factor X activating complex.
    Wong MY; Gurr JA; Walsh PN
    Biochemistry; 1999 Jul; 38(28):8948-60. PubMed ID: 10413468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of inhibition rate enhancement by covalent linkage of antithrombin to heparin as a potential predictor of reaction mechanism.
    Patel S; Berry LR; Chan AK
    J Biochem; 2007 Jan; 141(1):25-35. PubMed ID: 17167048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Na+ a coagulation factor?
    Page MJ; Di Cera E
    Thromb Haemost; 2006 Jun; 95(6):920-1. PubMed ID: 16732367
    [No Abstract]   [Full Text] [Related]  

  • 18. Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.
    Monteiro RQ; Zingali RB
    Thromb Haemost; 2002 Feb; 87(2):288-93. PubMed ID: 11858489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding.
    Schmidt AE; Stewart JE; Mathur A; Krishnaswamy S; Bajaj SP
    J Mol Biol; 2005 Jul; 350(1):78-91. PubMed ID: 15913649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
    Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.